Neopharmed Gentili, a leading Italian pharmaceutical company active in the marketing of high-value therapeutic solutions controlled by Ardian and the Del Bono family, acquired 100% of MDM, a pharmaceutical company based in Monza active in the distribution of pharmaceuticals, nutraceuticals and medical devices for neurology and orthopedics.

With over 20 years of experience, MDM has a product portfolio complementary to Neopharmed’s, including several reference drugs for the treatment of neurological and osteoarticular disorders. Thanks to this acquisition, Neopharmed will consolidate its presence in the Italian market and expand its offering in highly strategic therapeutic areas.

Neopharmed has a proven track record in creating value through partnerships and acquisitions. This transaction perfectly fits with the strategy addressing both organic and external growth opportunities pursued by the Del Bono Family and Ardian since deal inception in November 2018. This partnership aims at establishing Neopharmed as one of the leaders in its market segment and at expanding the Group’s presence in adjacent therapeutic areas with high growth potential and undisputed strategic value.

Alessandro Del Bono, shareholder, Chairman and CEO of Neopharmed, stated: “I am particularly pleased to announce that MDM joined our Group. It is a highly strategic transaction and I would like to thank the Trognoni Family and the Monico Family, whose collaboration was pivotal to the successful completion of this acquisition. Furthermore, I am very happy to have Mr. Antonio Maggi, CEO of MDM, within our team. Thanks to his skills and experience, he will positively contribute to the Group’s future development. This transaction confirms Neopharmed’s growth strategy aimed at positioning itself among the main Italian pharmaceutical players”.

Read the press release